Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women

Breast Cancer Research

Table 4 Risk of death of any cause or of breast cancer, comparing younger women (15 to 39 years of age) with women 40 to 64 years of age with breast cancer, by subtype, race/ethnicity, or stage at diagnosis; California, 2005 through 2009

	All-cause deaths		Breast cancer-specific deaths
	Model 1* HR (95% CI)	Model 2** HR (95% CI)	Model 1** HR (95% CI)	Model 2** HR (95% CI)
Overall	0.96 (0.86-1.06)	0.92 (0.83-1.02)	0.99 (0.88-1.10)	0.94 (0.84-1.05)
Subtype†
HR+/HER2-	N/A	0.92 (0.75-1.11)	N/A	0.92 (0.74-1.15)
HR+/HER2+		0.87 (0.62-1.22)		1.00 (0.69-1.46)
HR-/HER2+		0.99 (0.74-1.31)		1.08 (0.80-1.46)
Triple negative		0.93 (0.78-1.10)		0.93 (0.77-1.12)
Unclassified		0.86 (0.66-1.13)		0.88 (0.65-1.19)
Race/ethnicity‡
NH White	0.90 (0.76-1.06)	0.89 (0.75-1.05)	0.93 (0.78-1.12)	0.92 (0.77-1.11)
NH Black	0.93 (0.71-1.21)	0.89 (0.68-1.16)	0.97 (0.72-1.29)	0.91 (0.68-1.22)
Hispanic	1.01 (0.85-1.20)	0.95 (0.80-1.14)	1.05 (0.87-1.27)	0.99 (0.82-1.20)
NH Asian/Pacific Islander	1.01 (0.75-1.35)	0.98 (0.73-1.31)	1.02 (0.73-1.41)	0.98 (0.71-1.37)
Unknown	N/A	N/A	N/A	N/A
AJCC stage at diagnosis
I	0.97 (0.65-1.43)	0.95 (0.64-1.40)	1.44 (0.90-2.31)	1.38 (0.86-2.21)
II	0.95 (0.79-1.15)	0.90 (0.74-1.08)	0.98 (0.79-1.21)	0.91 (0.73-1.13)
III	1.02 (0.86-1.21)	0.97 (0.82-1.15)	1.06 (0.88-1.27)	1.01 (0.84-1.21)
IV	0.86 (0.70-1.06)	0.86 (0.70-1.05)	0.86 (0.69-1.07)	0.86 (0.69-1.07)
Unknown	1.10 (0.70-1.74)	1.09 (0.69-1.72)	1.02 (0.59-1.77)	1.03 (0.59-1.78)

* Reference group for each model was women 40 to 64 years of age at diagnosis. Cox models were adjusted for all variables in the table and year of diagnosis (continuous), marital status at diagnosis, tumor grade, neighborhood SES (quintile), and first course of treatment (chemotherapy (y/n), radiation (y/n), and surgery (y/n)). AJCC stage levels I through IV and unknown were included as a stratifying variable.
** Cox models were additionally adjusted for subtypes of breast cancer.
† Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).
‡ Non-Hispanic.

ISSN: 1465-542X